Steady Revenue Growth
Total company revenue for the quarter was $1.281 billion, reflecting a year-over-year growth of 6% across all segments.
Pharmaceutical Segment Success
Miebo delivered $84 million of revenue in Q3 with a 71% increase year-over-year and TRx growth of 110%. Vision Care revenue increased by 6%.
Strong Performance in Vision Care
Vision Care revenue of $736 million increased by 6%, driven by growth in consumer and contact lenses. Blink reported a 37% growth, Artelac 24%, and eye vitamins 12%.
Growth in Premium IOLs
27% constant currency revenue growth in premium IOLs, with enVista intraocular lenses contributing significantly.
Successful Cash Flow Optimization
Adjusted cash flow from operations was $161 million with a 66% conversion to EBITDA.